US › Healthcare

BioLineRx Ltd (BLRX)

US · Healthcare · Biotechnology

$2.01-1.95%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$299,048

Revenue YoY

-1.6%

Net profit

$-3.1M

EPS

$-0.77

EPS estimate

$-0.30

Net margin

-1,029.3%

EPS came in at -0.77 against a street estimate of -0.30 — a miss of 156.7%.

Key statistics

Market cap

$10.2M

Forward P/E

93.5

P/B

0.89

Book value

$3.00

EPS (TTM)

$0.00

52-week high

$3.95

52-week low

$1.95

50-day MA

$2.55

200-day MA

$2.79

Beta

0.70

Analyst view

Analysts rate BioLineRx Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $22.00.

Shareholding

Insiders

3.43%

Institutions

1.34%

Largest institutional holders

Fund	Stake
Susquehanna International Group, LLP	0.62%
Renaissance Technologies Corp	0.31%
Citadel Advisors Llc	0.30%
Rhumbline Advisers	0.05%
Wells Fargo & Co	0.04%
BNP Paribas Arbitrage, SA	0.01%
Banque Cantonale Vaudoise	0.01%
UBS Group AG	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioLineRx Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.